Cluster composition

Functions

Category	Name	IntersectionWithQuery	PValue	GenesInTerm	GenesInQuery	GenesInTermInQuery	ID
GeneOntologyMolecularFunction	testosterone 16-alpha-hydroxylase activity	CYP3A4 CYP3A5	2.97e-05	4	45	2	GO:0008390
GeneOntologyMolecularFunction	vitamin D 23-hydroxylase activity	CYP3A4 CYP3A5	4.94e-05	5	45	2	GO:0062179
GeneOntologyMolecularFunction	testosterone 6-beta-hydroxylase activity	CYP3A4 CYP3A5	4.94e-05	5	45	2	GO:0050649
GeneOntologyMolecularFunction	1-alpha,25-dihydroxyvitamin D3 23-hydroxylase activity	CYP3A4 CYP3A5	4.94e-05	5	45	2	GO:0062181
GeneOntologyMolecularFunction	vitamin D 24-hydroxylase activity	CYP3A4 CYP3A5	7.41e-05	6	45	2	GO:0070576
GeneOntologyMolecularFunction	vitamin D3 25-hydroxylase activity	CYP3A4 CYP3A5	7.41e-05	6	45	2	GO:0030343
GeneOntologyMolecularFunction	vitamin D 25-hydroxylase activity	CYP3A4 CYP3A5	1.04e-04	7	45	2	GO:0070643
GeneOntologyMolecularFunction	oxidoreductase activity, acting on CH or CH2 groups, quinone or similar compound as acceptor	CYP3A4 CYP3A5	1.38e-04	8	45	2	GO:0033695
GeneOntologyMolecularFunction	caffeine oxidase activity	CYP3A4 CYP3A5	1.38e-04	8	45	2	GO:0034875
GeneOntologyMolecularFunction	estrogen 2-hydroxylase activity	CYP3A4 CYP3A5	1.38e-04	8	45	2	GO:0101021
GeneOntologyMolecularFunction	estrogen 16-alpha-hydroxylase activity	CYP3A4 CYP3A5	2.70e-04	11	45	2	GO:0101020
GeneOntologyMolecularFunction	retinoic acid 4-hydroxylase activity	CYP3A4 CYP3A5	4.44e-04	14	45	2	GO:0008401
GeneOntologyMolecularFunction	oxidoreductase activity, acting on CH or CH2 groups	CYP3A4 CYP3A5	5.12e-04	15	45	2	GO:0016725
GeneOntologyMolecularFunction	monooxygenase activity	CYP3A4 CYP3A5 AGMO	2.21e-03	115	45	3	GO:0004497
GeneOntologyMolecularFunction	steroid hydroxylase activity	CYP3A4 CYP3A5	2.66e-03	34	45	2	GO:0008395
GeneOntologyMolecularFunction	aromatase activity	CYP3A4 CYP3A5	2.82e-03	35	45	2	GO:0070330
GeneOntologyMolecularFunction	oxygen binding	CYP3A4 CYP3A5	3.15e-03	37	45	2	GO:0019825
GeneOntologyMolecularFunction	steroid binding	CYP3A4 CYP3A5 NR1H4	3.34e-03	133	45	3	GO:0005496
GeneOntologyMolecularFunction	SNARE binding	CACNA1A NAPB ADCY6	3.56e-03	136	45	3	GO:0000149
GeneOntologyMolecularFunction	demethylase activity	CYP3A4 CYP3A5	4.42e-03	44	45	2	GO:0032451
GeneOntologyMolecularFunction	oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen	CYP3A4 CYP3A5	5.46e-03	49	45	2	GO:0016712
GeneOntologyBiologicalProcess	alkaloid catabolic process	CYP3A4 CYP3A5	4.63e-05	5	45	2	GO:0009822
GeneOntologyBiologicalProcess	retinoic acid metabolic process	RDH10 CYP3A4 CYP3A5	9.06e-05	40	45	3	GO:0042573
GeneOntologyBiologicalProcess	bud elongation involved in lung branching	RDH10 FGFR2	9.71e-05	7	45	2	GO:0060449
GeneOntologyBiologicalProcess	aflatoxin metabolic process	CYP3A4 CYP3A5	1.29e-04	8	45	2	GO:0046222
GeneOntologyBiologicalProcess	mycotoxin metabolic process	CYP3A4 CYP3A5	1.29e-04	8	45	2	GO:0043385
GeneOntologyBiologicalProcess	organic heteropentacyclic compound metabolic process	CYP3A4 CYP3A5	1.29e-04	8	45	2	GO:1901376
GeneOntologyBiologicalProcess	monocarboxylic acid metabolic process	IVD RDH10 BDH2 PFKL CYP3A4 CYP3A5 NR1H4 UGT2A3	1.62e-04	731	45	8	GO:0032787
GeneOntologyBiologicalProcess	alkaloid metabolic process	CYP3A4 CYP3A5	1.66e-04	9	45	2	GO:0009820
GeneOntologyBiologicalProcess	lipid hydroxylation	CYP3A4 CYP3A5	1.66e-04	9	45	2	GO:0002933
GeneOntologyBiologicalProcess	estrogen metabolic process	CYP3A4 CYP3A5 UGT2A3	1.99e-04	52	45	3	GO:0008210
GeneOntologyBiologicalProcess	retinol metabolic process	RDH10 CYP3A4 CYP3A5	2.11e-04	53	45	3	GO:0042572
GeneOntologyBiologicalProcess	oxidative demethylation	CYP3A4 CYP3A5	3.03e-04	12	45	2	GO:0070989
GeneOntologyBiologicalProcess	carboxylic acid metabolic process	IVD RDH10 BDH2 CACNA1A PFKL CYP3A4 CYP3A5 NR1H4 UGT2A3	3.37e-04	1035	45	9	GO:0019752
GeneOntologyBiologicalProcess	hormone metabolic process	RDH10 CACNA1A CYP3A4 CYP3A5 UGT2A3	3.84e-04	286	45	5	GO:0042445
GeneOntologyBiologicalProcess	oxoacid metabolic process	IVD RDH10 BDH2 CACNA1A PFKL CYP3A4 CYP3A5 NR1H4 UGT2A3	3.96e-04	1058	45	9	GO:0043436
GeneOntologyBiologicalProcess	organic acid metabolic process	IVD RDH10 BDH2 CACNA1A PFKL CYP3A4 CYP3A5 NR1H4 UGT2A3	4.13e-04	1064	45	9	GO:0006082
GeneOntologyBiologicalProcess	secondary metabolic process	BDH2 CYP3A4 CYP3A5	4.22e-04	67	45	3	GO:0019748
GeneOntologyBiologicalProcess	cellular response to prostaglandin E stimulus	PTGER2 ADCY6	5.48e-04	16	45	2	GO:0071380
MousePheno	impaired branching involved in trachea morphogenesis	RDH10 FGFR2	1.82e-05	3	35	2	MP:0011026
MousePheno	abnormal branching involved in trachea morphogenesis	RDH10 FGFR2	3.64e-05	4	35	2	MP:0011025
MousePheno	absent lungs	RDH10 FGFR2	6.06e-05	5	35	2	MP:0001181
MousePheno	abnormal trachea development	RDH10 FGFR2	9.08e-05	6	35	2	MP:0013496
Domain	Cyt_P450_E_grp-II	CYP3A4 CYP3A5	5.65e-05	5	45	2	IPR002402
Domain	Cyt_P450_E_CYP3A	CYP3A4 CYP3A5	8.46e-05	6	45	2	IPR008072
Domain	-	FEM1C NAPB TRAPPC12 EDRF1 NAA16	1.36e-04	207	45	5	1.25.40.10
Domain	TPR-like_helical_dom	FEM1C NAPB TRAPPC12 EDRF1 NAA16	2.35e-04	233	45	5	IPR011990
Domain	MIF4G	NCBP1 EIF4G2	2.52e-04	10	45	2	SM00543
Domain	MIF4G	NCBP1 EIF4G2	2.52e-04	10	45	2	PF02854
Domain	MIF4G-like_typ-3	NCBP1 EIF4G2	2.52e-04	10	45	2	IPR003890
Domain	MIF4-like	NCBP1 EIF4G2	5.84e-04	15	45	2	IPR016021
Domain	-	NCBP1 EIF4G2	5.84e-04	15	45	2	1.25.40.180
Domain	TPR	FEM1C TRAPPC12 EDRF1 NAA16	6.60e-04	165	45	4	PS50005
Domain	TPR_REGION	FEM1C TRAPPC12 EDRF1 NAA16	6.60e-04	165	45	4	PS50293
Domain	ARM-type_fold	PSMD1 NCBP1 SDAD1 ANKAR EIF4G2	1.29e-03	339	45	5	IPR016024
Domain	Sc_DH/Rdtase_CS	RDH10 BDH2	3.21e-03	35	45	2	IPR020904
Domain	TPR-contain_dom	TRAPPC12 EDRF1 NAA16	5.63e-03	150	45	3	IPR013026
Domain	Cyt_P450_CS	CYP3A4 CYP3A5	7.23e-03	53	45	2	IPR017972
Domain	ADH_SHORT	RDH10 BDH2	7.23e-03	53	45	2	PS00061
Domain	adh_short	RDH10 BDH2	7.77e-03	55	45	2	PF00106
Domain	SDR_fam	RDH10 BDH2	8.05e-03	56	45	2	IPR002347
Domain	CYTOCHROME_P450	CYP3A4 CYP3A5	8.33e-03	57	45	2	PS00086
Domain	-	CYP3A4 CYP3A5	8.61e-03	58	45	2	1.10.630.10
Domain	p450	CYP3A4 CYP3A5	8.61e-03	58	45	2	PF00067
Domain	Cyt_P450	CYP3A4 CYP3A5	9.19e-03	60	45	2	IPR001128
Pathway	REACTOME_SIGNALING_BY_FGFR2_IIIA_TM	NCBP1 FGFR2 POLR2B	1.70e-05	19	38	3	M27739
Pathway	KEGG_RETINOL_METABOLISM	RDH10 CYP3A4 CYP3A5 UGT2A3	2.54e-05	64	38	4	M9488
Pathway	REACTOME_FGFR2_ALTERNATIVE_SPLICING	NCBP1 FGFR2 POLR2B	5.05e-05	27	38	3	M27632
Pathway	BIOCARTA_NUCLEARRS_PATHWAY	CYP3A4 CYP3A5 NR1H4	9.32e-05	33	38	3	MM1448
Pathway	REACTOME_FGFR2_MUTANT_RECEPTOR_ACTIVATION	NCBP1 FGFR2 POLR2B	9.32e-05	33	38	3	M27049
Pathway	BIOCARTA_ACETAMINOPHEN_PATHWAY	CYP3A4 CYP3A5	1.96e-04	8	38	2	MM1547
Pathway	REACTOME_SIGNALING_BY_FGFR2_IN_DISEASE	NCBP1 FGFR2 POLR2B	2.07e-04	43	38	3	M27534
Pathway	REACTOME_ASPIRIN_ADME	CYP3A4 CYP3A5 UGT2A3	2.37e-04	45	38	3	MM15694
Pathway	KEGG_DRUG_METABOLISM_OTHER_ENZYMES	CYP3A4 CYP3A5 UGT2A3	3.44e-04	51	38	3	M17726
Pathway	KEGG_STEROID_HORMONE_BIOSYNTHESIS	CYP3A4 CYP3A5 UGT2A3	4.30e-04	55	38	3	M14933
Pathway	WP_IRINOTECAN_PATHWAY	CYP3A4 CYP3A5	4.59e-04	12	38	2	M39611
Pathway	REACTOME_BIOSYNTHESIS_OF_MARESINS	CYP3A4 CYP3A5	4.59e-04	12	38	2	MM15616
Pathway	REACTOME_SIGNALING_BY_FGFR_IN_DISEASE	NCBP1 FGFR2 POLR2B	6.42e-04	63	38	3	M635
Pathway	REACTOME_CYTOCHROME_P450_ARRANGED_BY_SUBSTRATE_TYPE	CYP3A4 CYP3A5 NR1H4	6.72e-04	64	38	3	M5650
Pathway	REACTOME_ATORVASTATIN_ADME	CYP3A4 CYP3A5	7.27e-04	15	38	2	MM15697
Pathway	REACTOME_CYTOCHROME_P450_ARRANGED_BY_SUBSTRATE_TYPE	CYP3A4 CYP3A5 NR1H4	7.36e-04	66	38	3	MM14839
Pathway	KEGG_METABOLISM_OF_XENOBIOTICS_BY_CYTOCHROME_P450	CYP3A4 CYP3A5 UGT2A3	8.73e-04	70	38	3	M16794
Pathway	WP_DRUG_INDUCTION_OF_BILE_ACID_PATHWAY	CYP3A4 NR1H4	9.38e-04	17	38	2	M39666
Pathway	KEGG_DRUG_METABOLISM_CYTOCHROME_P450	CYP3A4 CYP3A5 UGT2A3	9.48e-04	72	38	3	M9257
Pathway	REACTOME_SIGNALING_BY_FGFR2	NCBP1 FGFR2 POLR2B	9.87e-04	73	38	3	M27531
Pathway	REACTOME_RNA_POLYMERASE_II_TRANSCRIBES_SNRNA_GENES	INTS10 NCBP1 POLR2B	9.87e-04	73	38	3	MM15349
Pathway	REACTOME_FGFR2_ALTERNATIVE_SPLICING	NCBP1 POLR2B	1.05e-03	18	38	2	MM15334
Pathway	REACTOME_MISCELLANEOUS_SUBSTRATES	CYP3A4 CYP3A5	1.05e-03	18	38	2	MM14843
Pathway	WP_FARNESOID_X_RECEPTOR_PATHWAY	CYP3A4 NR1H4	1.18e-03	19	38	2	M39411
Pathway	REACTOME_AFLATOXIN_ACTIVATION_AND_DETOXIFICATION	CYP3A4 CYP3A5	1.18e-03	19	38	2	M27449
Pathway	REACTOME_RNA_POLYMERASE_II_TRANSCRIBES_SNRNA_GENES	INTS10 NCBP1 POLR2B	1.33e-03	81	38	3	M27647
Pathway	WP_TAMOXIFEN_METABOLISM	CYP3A4 CYP3A5	1.44e-03	21	38	2	M39631
Pathway	REACTOME_BIOSYNTHESIS_OF_SPECIALIZED_PRORESOLVING_MEDIATORS_SPMS	CYP3A4 CYP3A5	1.58e-03	22	38	2	MM15614
Pathway	REACTOME_XENOBIOTICS	CYP3A4 CYP3A5	1.73e-03	23	38	2	M5372
Pathway	REACTOME_PREDNISONE_ADME	CYP3A4 CYP3A5	1.73e-03	23	38	2	MM16639
Pathway	REACTOME_ABORTIVE_ELONGATION_OF_HIV_1_TRANSCRIPT_IN_THE_ABSENCE_OF_TAT	NCBP1 POLR2B	1.73e-03	23	38	2	M3630
Pathway	REACTOME_SIGNALING_BY_FGFR	NCBP1 FGFR2 POLR2B	1.75e-03	89	38	3	M1090
Pathway	WP_ESTROGEN_METABOLISM_WP5276	CYP3A4 CYP3A5	1.88e-03	24	38	2	M46445
Pathway	REACTOME_XENOBIOTICS	CYP3A4 CYP3A5	2.04e-03	25	38	2	MM14846
Pubmed	Effects of Genetic Polymorphism in CYP3A4 and CYP3A5 Genes on Tacrolimus Dose Among Kidney Transplant Recipients.	CYP3A4 CYP3A5	1.71e-06	2	46	2	27225724
Pubmed	Screening CYP3A single nucleotide polymorphisms in a Han Chinese population with a genotyping chip.	CYP3A4 CYP3A5	1.71e-06	2	46	2	16207150
Pubmed	The combination of CYP3A422 and CYP3A53 single-nucleotide polymorphisms determines tacrolimus dose requirement after kidney transplantation.	CYP3A4 CYP3A5	1.71e-06	2	46	2	28704257
Pubmed	Genotype-phenotype associations of cytochrome P450 3A4 and 3A5 polymorphism with midazolam clearance in vivo.	CYP3A4 CYP3A5	1.71e-06	2	46	2	15900284
Pubmed	Genetic association in CYP3A4 and CYP3A5 genes elevate the risk of prostate cancer.	CYP3A4 CYP3A5	1.71e-06	2	46	2	36688864
Pubmed	Relative impact of CYP3A genotype and concomitant medication on the severity of atorvastatin-induced muscle damage.	CYP3A4 CYP3A5	1.71e-06	2	46	2	15900215
Pubmed	Cytochrome P450 3A4, 3A5, and 2C8 expression in breast, prostate, lung, endometrial, and ovarian tumors: relevance for resistance to taxanes.	CYP3A4 CYP3A5	1.71e-06	2	46	2	31309254
Pubmed	Impact of CYP3A5 and CYP3A4 gene polymorphisms on dose requirement of calcineurin inhibitors, cyclosporine and tacrolimus, in renal allograft recipients of North India.	CYP3A4 CYP3A5	1.71e-06	2	46	2	19343327
Pubmed	Discovery of a highly selective CYP3A4 inhibitor suitable for reaction phenotyping studies and differentiation of CYP3A4 and CYP3A5.	CYP3A4 CYP3A5	1.71e-06	2	46	2	22696420
Pubmed	CYP3A4/5 genotypes and age codetermine tacrolimus concentration and dosage in pediatric heart transplant recipients.	CYP3A4 CYP3A5	1.71e-06	2	46	2	35998509
Pubmed	CYP3A4 and CYP3A5 polymorphisms and blood pressure response to amlodipine among African-American men and women with early hypertensive renal disease.	CYP3A4 CYP3A5	1.71e-06	2	46	2	19907160
Pubmed	CYP3A41G and CYP3A53 genetic polymorphisms alter the antihypertensive efficacy of amlodipine in patients with hypertension following renal transplantation .	CYP3A4 CYP3A5	1.71e-06	2	46	2	27841150
Pubmed	Association of genotypes of the CYP3A cluster with midazolam disposition in vivo.	CYP3A4 CYP3A5	1.71e-06	2	46	2	19506580
Pubmed	CYP3A422 and CYP3A53 impact efficacy and safety of diazepam in patients with alcohol withdrawal syndrome.	CYP3A4 CYP3A5	1.71e-06	2	46	2	35471917
Pubmed	CYP3A5 and CYP3A4 but not MDR1 single-nucleotide polymorphisms determine long-term tacrolimus disposition and drug-related nephrotoxicity in renal recipients.	CYP3A4 CYP3A5	1.71e-06	2	46	2	17495880
Pubmed	Precision Dosing for Tacrolimus Using Genotypes and Clinical Factors in Kidney Transplant Recipients of European Ancestry.	CYP3A4 CYP3A5	1.71e-06	2	46	2	33512723
Pubmed	Relationship between In Vivo CYP3A4 Activity, CYP3A5 Genotype, and Systemic Tacrolimus Metabolite/Parent Drug Ratio in Renal Transplant Recipients and Healthy Volunteers.	CYP3A4 CYP3A5	1.71e-06	2	46	2	30166405
Pubmed	Effects of CYP3A4 and CYP3A5 polymorphisms on tacrolimus pharmacokinetics in Chinese adult renal transplant recipients: a population pharmacokinetic analysis.	CYP3A4 CYP3A5	1.71e-06	2	46	2	23459029
Pubmed	CYP3A4∗18B and CYP3A5∗3 polymorphisms contribute to pharmacokinetic variability of cyclosporine among healthy Chinese subjects.	CYP3A4 CYP3A5	1.71e-06	2	46	2	25976223
Pubmed	Association of CYP3A4/5 genotypes and expression with the survival of patients with neuroblastoma.	CYP3A4 CYP3A5	1.71e-06	2	46	2	25370902
Pubmed	The impact of cytochrome P450 3A genetic polymorphisms on tacrolimus pharmacokinetics in ulcerative colitis patients.	CYP3A4 CYP3A5	1.71e-06	2	46	2	33886687
Pubmed	Active-site differences between substrate-free and ritonavir-bound cytochrome P450 (CYP) 3A5 reveal plasticity differences between CYP3A5 and CYP3A4.	CYP3A4 CYP3A5	1.71e-06	2	46	2	30926609
Pubmed	Genetic diversity of CYP3A4 and CYP3A5 polymorphisms in North African populations from Morocco and Tunisia.	CYP3A4 CYP3A5	1.71e-06	2	46	2	25385241
Pubmed	A case-control association study between the CYP3A4 and CYP3A5 genes and schizophrenia in the Chinese Han population.	CYP3A4 CYP3A5	1.71e-06	2	46	2	19591893
Pubmed	CYP3A53 and CYP3A418 single nucleotide polymorphisms in a Chinese population.	CYP3A4 CYP3A5	1.71e-06	2	46	2	15698606
Pubmed	CYP3A4 and CYP3A5 genotypes, haplotypes, and risk of prostate cancer.	CYP3A4 CYP3A5	1.71e-06	2	46	2	14504207
Pubmed	CYP3A4 and CYP3A5 Expression is Regulated by CYP3A4*1G in CRISPR/Cas9-Edited HepG2 Cells.	CYP3A4 CYP3A5	1.71e-06	2	46	2	36623883
Pubmed	Association of CYP3A41G and CYP3A53 With the 1-year Outcome of Acute Ischemic Stroke in the Han Chinese Population.	CYP3A4 CYP3A5	1.71e-06	2	46	2	31064695
Pubmed	Genotype-phenotype associations for common CYP3A4 and CYP3A5 variants in the basal and induced metabolism of midazolam in European- and African-American men and women.	CYP3A4 CYP3A5	1.71e-06	2	46	2	14515058
Pubmed	The CYP3A4*1B allele increases risk for small cell lung cancer: effect of gender and smoking dose.	CYP3A4 CYP3A5	1.71e-06	2	46	2	14515059
Pubmed	Population pharmacokinetics and pharmacogenetics of once daily tacrolimus formulation in stable liver transplant recipients.	CYP3A4 CYP3A5	1.71e-06	2	46	2	26521259
Pubmed	Long-Term Stability of Cryopreserved Human Hepatocytes: Evaluation of Phase I and II Drug-Metabolizing Enzyme Activities and CYP3A4/5 Induction for More than a Decade.	CYP3A4 CYP3A5	1.71e-06	2	46	2	28411281
Pubmed	Associations of the CYP3A53 and CYP3A41G polymorphisms with the pharmacokinetics of oral midazolam and the urinary 6β-hydroxycortisol/cortisol ratio as markers of CYP3A activity in healthy male Chinese.	CYP3A4 CYP3A5	1.71e-06	2	46	2	27511886
Pubmed	Association between CYP3A4/CYP3A5 genetic polymorphisms and treatment outcomes of atorvastatin worldwide: is there enough research on the Egyptian population?	CYP3A4 CYP3A5	1.71e-06	2	46	2	37759317
Pubmed	Influence of donor-recipient CYP3A4/5 genotypes, age and fluconazole on tacrolimus pharmacokinetics in pediatric liver transplantation: a population approach.	CYP3A4 CYP3A5	1.71e-06	2	46	2	25141896
Pubmed	Association of CYP3A4, CYP3A5 polymorphisms with lung cancer risk in Bangladeshi population.	CYP3A4 CYP3A5	1.71e-06	2	46	2	24085358
Pubmed	Recombinant CYP3A417 is defective in metabolizing the hypertensive drug nifedipine, and the CYP3A417 allele may occur on the same chromosome as CYP3A5*3, representing a new putative defective CYP3A haplotype.	CYP3A4 CYP3A5	1.71e-06	2	46	2	15634941
Pubmed	Influence of combined CYP3A4 and CYP3A5 single-nucleotide polymorphisms on tacrolimus exposure in kidney transplant recipients: a study according to the post-transplant phase.	CYP3A4 CYP3A5	1.71e-06	2	46	2	26615671
Pubmed	Drugs as CYP3A probes, inducers, and inhibitors.	CYP3A4 CYP3A5	1.71e-06	2	46	2	18058330
Pubmed	Comparative analysis of substrate and inhibitor interactions with CYP3A4 and CYP3A5.	CYP3A4 CYP3A5	1.71e-06	2	46	2	16684709
Pubmed	Differential expression of human cytochrome P450 enzymes from the CYP3A subfamily in the brains of alcoholic subjects and drug-free controls.	CYP3A4 CYP3A5	1.71e-06	2	46	2	23491640
Pubmed	Cytochrome P450 3A-dependent metabolism of a potent and selective gamma-aminobutyric acid Aalpha2/3 receptor agonist in vitro: involvement of cytochrome P450 3A5 displaying biphasic kinetics.	CYP3A4 CYP3A5	1.71e-06	2	46	2	17460031
Pubmed	The rs776746 variant of CYP3A5 is associated with intravenous midazolam plasma levels and higher clearance in critically ill Mexican paediatric patients.	CYP3A4 CYP3A5	1.71e-06	2	46	2	33638195
Pubmed	Study the polymorphism of CYP3A5 and CYP3A4 loci in Iranian population with laryngeal squamous cell carcinoma.	CYP3A4 CYP3A5	1.71e-06	2	46	2	21380731
Pubmed	Influence of CYP3A polymorphisms on tacrolimus pharmacokinetics in kidney transplant recipients.	CYP3A4 CYP3A5	1.71e-06	2	46	2	32843687
Pubmed	Genetic variability in CYP3A4 and CYP3A5 in primary liver, gastric and colorectal cancer patients.	CYP3A4 CYP3A5	1.71e-06	2	46	2	17605821
Pubmed	Comparison of catalytic properties of cytochromes P450 3A4 and 3A5 by molecular docking simulation.	CYP3A4 CYP3A5	1.71e-06	2	46	2	24484539
Pubmed	Assessment of the impact of CYP3A polymorphisms on the formation of α-hydroxytamoxifen and N-desmethyltamoxifen in human liver microsomes.	CYP3A4 CYP3A5	1.71e-06	2	46	2	22096084
Pubmed	Regulation of CYP3A4 by the bile acid receptor FXR: evidence for functional binding sites in the CYP3A4 gene.	CYP3A4 NR1H4	1.71e-06	2	46	2	15454728
Pubmed	Expression and enzyme activity of cytochrome P450 enzymes CYP3A4 and CYP3A5 in human skin and tissue-engineered skin equivalents.	CYP3A4 CYP3A5	1.71e-06	2	46	2	29227563
Pubmed	[Influence of CYP3A4/5 polymorphisms in the pharmacokinetics of levonorgestrel: a pilot study].	CYP3A4 CYP3A5	1.71e-06	2	46	2	23715232
Pubmed	Genetic, pathological and physiological determinants of transdermal fentanyl pharmacokinetics in 620 cancer patients of the EPOS study.	CYP3A4 CYP3A5	1.71e-06	2	46	2	24469018
Pubmed	Evaluating the Impacts of CYP3A41B and CYP3A53 Variations on Pharmacokinetic Behavior and Clinical Outcomes in Multiple Myeloma Patients With Autologous Stem Cell Transplant.	CYP3A4 CYP3A5	1.71e-06	2	46	2	36581339
Pubmed	Selective mechanism-based inactivation of CYP3A4 by CYP3cide (PF-04981517) and its utility as an in vitro tool for delineating the relative roles of CYP3A4 versus CYP3A5 in the metabolism of drugs.	CYP3A4 CYP3A5	1.71e-06	2	46	2	22645092
Pubmed	CYP3A4 and CYP3A5 genotyping by Pyrosequencing.	CYP3A4 CYP3A5	1.71e-06	2	46	2	15882469
Pubmed	Biosynthesis and Identification of Metabolites of Maraviroc and Their Use in Experiments to Delineate the Relative Contributions of Cytochrome P4503A4 versus 3A5.	CYP3A4 CYP3A5	1.71e-06	2	46	2	29475834
Pubmed	Association between the CYP3A4 and CYP3A5 polymorphisms and cancer risk: a meta-analysis and meta-regression.	CYP3A4 CYP3A5	1.71e-06	2	46	2	24989928
Pubmed	Influence of CYP3A422 and CYP3A53 combined genotypes on tacrolimus dose requirements in Egyptian renal transplant patients.	CYP3A4 CYP3A5	1.71e-06	2	46	2	36379901
Pubmed	The Prognostic Role of CYP Enzyme in Kidney Transplantation: A Single Centre Experience.	CYP3A4 CYP3A5	1.71e-06	2	46	2	36396462
Pubmed	Induction of hepatic CYP3A enzymes by pregnancy-related hormones: studies in human hepatocytes and hepatic cell lines.	CYP3A4 CYP3A5	1.71e-06	2	46	2	23223499
Pubmed	Influence of CYP3A53 polymorphism and interaction between CYP3A53 and CYP3A4*1G polymorphisms on post-operative fentanyl analgesia in Chinese patients undergoing gynaecological surgery.	CYP3A4 CYP3A5	1.71e-06	2	46	2	21513075
Pubmed	The relative contributions of CYP3A4 and CYP3A5 to the metabolism of vinorelbine.	CYP3A4 CYP3A5	1.71e-06	2	46	2	23780963
Pubmed	Genetic polymorphisms in MDR1, CYP3A4 and CYP3A5 genes in a Ghanaian population: a plausible explanation for altered metabolism of ivermectin in humans?	CYP3A4 CYP3A5	1.71e-06	2	46	2	20630055
Pubmed	Decision tree-based modeling of androgen pathway genes and prostate cancer risk.	CYP3A4 CYP3A5	1.71e-06	2	46	2	21493872
Pubmed	CYP3A activity based on plasma 4β-hydroxycholesterol during the early postpartum period has an effect on the plasma disposition of amlodipine.	CYP3A4 CYP3A5	1.71e-06	2	46	2	26654672
Pubmed	[Effect of CYP3A418B, CYP3A53 gene polymorphism on dosage and concentration of tacrolimus in renal transplant patients].	CYP3A4 CYP3A5	1.71e-06	2	46	2	22993851
Pubmed	Genotype-phenotype variability in human CYP3A locus in Nepalese people residing in Bangladesh.	CYP3A4 CYP3A5	1.71e-06	2	46	2	23320986
Pubmed	Pharmacokinetics of midazolam in CYP3A4- and CYP3A5-genotyped subjects.	CYP3A4 CYP3A5	1.71e-06	2	46	2	15114431
Pubmed	Functionally defective or altered CYP3A4 and CYP3A5 single nucleotide polymorphisms and their detection with genotyping tests.	CYP3A4 CYP3A5	1.71e-06	2	46	2	16004554
Pubmed	Regulatory variants in a novel distal enhancer regulate the expression of CYP3A4 and CYP3A5.	CYP3A4 CYP3A5	1.71e-06	2	46	2	36045613
Pubmed	Association of CYP3A418B and CYP3A53 polymorphism with cyclosporine-related liver injury in Chinese renal transplant recipients.	CYP3A4 CYP3A5	1.71e-06	2	46	2	24691060
Pubmed	Genome-wide association study identifies the common variants in CYP3A4 and CYP3A5 responsible for variation in tacrolimus trough concentration in Caucasian kidney transplant recipients.	CYP3A4 CYP3A5	1.71e-06	2	46	2	29160300
Pubmed	Effect of common CYP3A4 and CYP3A5 variants on the pharmacokinetics of the cytochrome P450 3A phenotyping probe midazolam in cancer patients.	CYP3A4 CYP3A5	1.71e-06	2	46	2	16243813
Pubmed	Amlodipine metabolism in human liver microsomes and roles of CYP3A4/5 in the dihydropyridine dehydrogenation.	CYP3A4 CYP3A5	1.71e-06	2	46	2	24301608
Pubmed	Cyp3A4, Cyp3A5, and MDR-1 genetic influences on tacrolimus pharmacokinetics in renal transplant recipients.	CYP3A4 CYP3A5	5.13e-06	3	46	2	16906020
Pubmed	[Pharmacogenetic analysis of the absorption kinetics of cyclosporine in a population of Spanish cardiac transplant patients].	CYP3A4 CYP3A5	5.13e-06	3	46	2	20038391
Pubmed	Influence of CYP3A4, CYP3A5 and MDR-1 polymorphisms on tacrolimus pharmacokinetics and early renal dysfunction in liver transplant recipients.	CYP3A4 CYP3A5	5.13e-06	3	46	2	23107770
Pubmed	Candidate-Gene Study of Functional Polymorphisms in SLCO1B1 and CYP3A4/5 and the Cholesterol-Lowering Response to Simvastatin.	CYP3A4 CYP3A5	5.13e-06	3	46	2	28482130
Pubmed	Differences in CYP3A5*3 genotype distribution and combinations with other polymorphisms between Spaniards and Other Caucasian populations.	CYP3A4 CYP3A5	5.13e-06	3	46	2	16306861
Pubmed	Effect of Age and Allele Variants of CYP3A5, CYP3A4, and POR Genes on the Pharmacokinetics of Cyclosporin A in Pediatric Renal Transplant Recipients From Serbia.	CYP3A4 CYP3A5	5.13e-06	3	46	2	29135906
Pubmed	Association of MDR1, CYP3A418B, and CYP3A53 polymorphisms with cyclosporine pharmacokinetics in Chinese renal transplant recipients.	CYP3A4 CYP3A5	5.13e-06	3	46	2	18636247
Pubmed	Human gut microbiota influences drug-metabolizing enzyme hepatic Cyp3a: A human flora-associated mice study.	CYP3A4 CYP3A5	5.13e-06	3	46	2	37258238
Pubmed	Effect of Naringenin, Quercetin, and Sesamin on Xenobiotica-Metabolizing CYP1A and CYP3A in Mice Offspring after Maternal Exposure to Persistent Organic Pollutants.	CYP3A4 CYP3A5	5.13e-06	3	46	2	28567424
Pubmed	Downregulation of mouse hepatic CYP3A protein by 3-methylcholanthrene does not require cytochrome P450-dependent metabolism.	CYP3A4 CYP3A5	5.13e-06	3	46	2	23846873
Pubmed	[CYP2D6, CYP3A5, and CYP3A4 gene polymorphism in Russian, Tatar, and Bashkir populations].	CYP3A4 CYP3A5	5.13e-06	3	46	2	25857198
Pubmed	A useful model capable of predicting the clearance of cytochrome 3A4 (CYP3A4) substrates in humans: validity of CYP3A4 transgenic mice lacking their own Cyp3a enzymes.	CYP3A4 CYP3A5	5.13e-06	3	46	2	25005602
Pubmed	Cloning, sequencing, heterologous expression, and characterization of murine cytochrome P450 3a25*(Cyp3a25), a testosterone 6beta-hydroxylase.	CYP3A4 CYP3A5	5.13e-06	3	46	2	11284050
Pubmed	Collaborated regulation of female-specific murine Cyp3a41 gene expression by growth and glucocorticoid hormones.	CYP3A4 CYP3A5	5.13e-06	3	46	2	14733933
Pubmed	Regulation of the expression of two female-predominant CYP3A mRNAs (CYP3A41 and CYP3A44) in mouse liver by sex and growth hormones.	CYP3A4 CYP3A5	5.13e-06	3	46	2	12147261
Pubmed	Genetic variations in androgen metabolism genes and associations with prostate cancer in South African men.	CYP3A4 CYP3A5	5.13e-06	3	46	2	21081028
Pubmed	Roles of CYP3A4, CYP3A5 and CYP2C8 drug-metabolizing enzymes in cellular cytostatic resistance.	CYP3A4 CYP3A5	5.13e-06	3	46	2	33775687
Pubmed	Mouse liver cytochrome P-450 (P-450IIIAM1): its cDNA cloning and inducibility by dexamethasone.	CYP3A4 CYP3A5	5.13e-06	3	46	2	1339292
Pubmed	Explaining interindividual variability of docetaxel pharmacokinetics and pharmacodynamics in Asians through phenotyping and genotyping strategies.	CYP3A4 CYP3A5	5.13e-06	3	46	2	12202670
Pubmed	Influence of CYP2C8, CYP3A4, and CYP3A5 Host Genotypes on Early Recurrence of Plasmodium vivax.	CYP3A4 CYP3A5	5.13e-06	3	46	2	32366712
Pubmed	Predominantly neuronal expression of cytochrome P450 isoforms CYP3A11 and CYP3A13 in mouse brain.	CYP3A4 CYP3A5	5.13e-06	3	46	2	12617959
Pubmed	Consequences of genetic polymorphisms for sirolimus requirements after renal transplant in patients on primary sirolimus therapy.	CYP3A4 CYP3A5	5.13e-06	3	46	2	15707415
Pubmed	The P450 oxidoreductase genotype is associated with CYP3A activity in vivo as measured by the midazolam phenotyping test.	CYP3A4 CYP3A5	5.13e-06	3	46	2	19801957
Pubmed	The distribution of genetic polymorphism of CYP3A5, CYP3A4 and ABCB1 in patients subjected to renal transplantation.	CYP3A4 CYP3A5	5.13e-06	3	46	2	29314799
Pubmed	Mouse cytochrome P450 (Cyp3a11): predominant expression in liver and capacity to activate aflatoxin B1.	CYP3A4 CYP3A5	5.13e-06	3	46	2	9143324
Pubmed	Metabolic pathways of inhaled glucocorticoids by the CYP3A enzymes.	CYP3A4 CYP3A5	5.13e-06	3	46	2	23143891
Cytoband	7q21.1	CYP3A4 CYP3A5	2.74e-05	8	46	2	7q21.1
Cytoband	21q22.3	B3GALT5 PFKL RRP1	2.94e-04	128	46	3	21q22.3
GeneFamily	Cytochrome P450 family 3	CYP3A4 CYP3A5	7.92e-05	8	31	2	1002
Coexpression	BENPORATH_SOX2_TARGETS	RDH10 BDH2 CACNA1A NCBP1 FGFR2 CEP95 NUP160 DARS2 EIF4G2	4.39e-06	734	46	9	M3835
Coexpression	GSE3920_UNTREATED_VS_IFNG_TREATED_ENDOTHELIAL_CELL_DN	PSMD1 PFKL NUP160 POLR2B MEN1	1.75e-05	184	46	5	M6696
ToppCell	3'-Pediatric_IBD-SmallIntestine-Epithelial\|Pediatric_IBD / Celltypes from developing, pediatric, Crohn's, & adult GI tract	B3GALT5 CLDN7 CYP3A4 CYP3A5 NR1H4 UGT2A3	5.45e-08	198	46	6	e3e2233c796d5e9051c8c1b66f70f406f048ed56
ToppCell	5'-Adult-SmallIntestine-Epithelial\|Adult / Celltypes from developing, pediatric, Crohn's, & adult GI tract	CLDN7 CYP3A4 CYP3A5 NR1H4 UGT2A3	1.86e-06	198	46	5	8d629492d2199de8e036c19e9dacceb9c9e721a0
ToppCell	3'-Child09-12-SmallIntestine-Epithelial-mature_enterocytic-Enterocyte\|Child09-12 / Celltypes from developing, pediatric, Crohn's, & adult GI tract	CLDN7 CYP3A4 CYP3A5 NR1H4 UGT2A3	1.86e-06	198	46	5	2967fb2d94662997bfe932ac299c80d6f182fb48
ToppCell	3'-Pediatric_IBD-SmallIntestine-Epithelial-mature_enterocytic\|Pediatric_IBD / Celltypes from developing, pediatric, Crohn's, & adult GI tract	CLDN7 CYP3A4 CYP3A5 NR1H4 UGT2A3	1.86e-06	198	46	5	8fac96132663f54566136ef54b53684d31dfde32
ToppCell	3'-Child09-12-SmallIntestine-Epithelial-mature_enterocytic\|Child09-12 / Celltypes from developing, pediatric, Crohn's, & adult GI tract	CLDN7 CYP3A4 CYP3A5 NR1H4 UGT2A3	1.86e-06	198	46	5	222a060c2c63d30da34e4b71c37aa27a048d7d09
ToppCell	3'-Pediatric_IBD-SmallIntestine-Epithelial-mature_enterocytic-Enterocyte\|Pediatric_IBD / Celltypes from developing, pediatric, Crohn's, & adult GI tract	CLDN7 CYP3A4 CYP3A5 NR1H4 UGT2A3	1.86e-06	198	46	5	c48b3f026b16d48b8eca9f74dc1e3f3f39a89322
ToppCell	3'-Child04-06-SmallIntestine-Epithelial-mature_enterocytic-Enterocyte\|Child04-06 / Celltypes from developing, pediatric, Crohn's, & adult GI tract	CLDN7 CYP3A4 CYP3A5 NR1H4 UGT2A3	1.90e-06	199	46	5	0181c13379f869be47804cdb11bbdabcd30b9b23
ToppCell	3'-Child04-06-SmallIntestine-Epithelial-mature_enterocytic\|Child04-06 / Celltypes from developing, pediatric, Crohn's, & adult GI tract	CLDN7 CYP3A4 CYP3A5 NR1H4 UGT2A3	1.90e-06	199	46	5	ee981046217e8759610eb58a670d98f32cd83abc
ToppCell	COVID-19-kidney-Technical/muscle_(Imm)\|kidney / Disease (COVID-19 only), tissue and cell type	CACNA1A PIEZO2 SAMD3 DNAH9	2.41e-05	163	46	4	19c28ce16a588a7f4a035c32726f6ccd67702b5b
ToppCell	renal_medulla_nuclei-Renal_AKI_(acute_kidney_injury)-Epithelial-Proximal_tubule_epithelial_cell-kidney_proximal_tubule_epithelial_cell_cycling-Cycling_Proximal_Tubule_Epithelial_Cell_low-phase\|Renal_AKI_(acute_kidney_injury) / Celltypes from Cells and Nuclei per compartment and clinical group	BDH2 SAMD3 SDAD1 ANKAR	2.58e-05	166	46	4	43f84d3cd58e93ce00c241656c4cba27604b4932
ToppCell	COVID-19-kidney-PCT-S3-2\|COVID-19 / Disease (COVID-19 only), tissue and cell type	CYP3A4 CYP3A5 NR1H4 AGMO	3.25e-05	176	46	4	b6497324e3e52f514ce556a3fa0c3011c45dcc7b
ToppCell	renal_cortex_nuclei-CKD+DKD_normotensive-Epithelial-Proximal_tubule_epithelial_cell-kidney_proximal_tubule_epithelial_cell-Adaptive_/_Maladaptive_/_Repairing_Proximal_Tubule_Epithelial_Cell\|CKD+DKD_normotensive / Celltypes from Cells and Nuclei per compartment and clinical group	FGFR2 NR1H4 UGT2A3 AGMO	4.03e-05	186	46	4	b87acc80b7baa41681e4ed11d5537b9fbf5832f5
ToppCell	renal_cortex_nuclei-Adult_normal_reference-Mesenchymal-glomerular_mesenchymal_cell-Mesangial_Cell\|Adult_normal_reference / Celltypes from Cells and Nuclei per compartment and clinical group	CACNA1A PIEZO2 SAMD3 PTGER2	4.11e-05	187	46	4	15d6e158562d7d85af3ceaf955439b379c8fce81
ToppCell	renal_cortex_nuclei-Adult_normal_reference-Mesenchymal-glomerular_mesenchymal_cell\|Adult_normal_reference / Celltypes from Cells and Nuclei per compartment and clinical group	CACNA1A PIEZO2 SAMD3 PTGER2	4.11e-05	187	46	4	f62074b631fd45ad299c69d71b09267b04d656ee
ToppCell	renal_cortex_nuclei-Adult_normal_reference-Mesenchymal-glomerular_mesenchymal_cell-Mesangial_Cell-mesangial_typical-aged\|Adult_normal_reference / Celltypes from Cells and Nuclei per compartment and clinical group	CACNA1A PIEZO2 SAMD3 PTGER2	4.20e-05	188	46	4	32f22a4d8cb98fd8b8fa0fbf28ef9266d711d081
ToppCell	COVID-19_Convalescent-Classical_Monocyte-cMono_3\|Classical_Monocyte / Disease condition and Cell class	BDH2 NAPB NUP160 EDRF1	4.29e-05	189	46	4	8b6f92ccfffc743c07201bc971b3dc1a6fa14ccc
ToppCell	COVID-19_Convalescent-Classical_Monocyte-cMono_3\|COVID-19_Convalescent / Disease condition and Cell class	BDH2 NAPB NUP160 EDRF1	4.29e-05	189	46	4	732e8dcffcb634ca2968f9170c9c4b31dd5d4206
ToppCell	3'-Airway_Nasal-Epithelial-Epithelial_transtional-secretory-nasal_mucosa_goblet_cell-Goblet_(nasal)-Goblet_(nasal)_L.0.2.2.1\|3' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5	RDH10 B3GALT5 CLDN7 CYP3A4	4.38e-05	190	46	4	2fdc024d3d673a0134b74b4c5a63afe924995730
ToppCell	5'-Adult-SmallIntestine-Epithelial-mature_enterocytic-Enterocyte\|Adult / Celltypes from developing, pediatric, Crohn's, & adult GI tract	CYP3A4 CYP3A5 NR1H4 UGT2A3	5.14e-05	198	46	4	6e6af8fad09f8e48b3f2ce463d5773b6a69864d1
ToppCell	3'-Child09-12-SmallIntestine-Epithelial\|Child09-12 / Celltypes from developing, pediatric, Crohn's, & adult GI tract	CLDN7 CYP3A4 CYP3A5 UGT2A3	5.24e-05	199	46	4	043c65bdf54a1bf0e483fea9ffc042ff5b271764
ToppCell	5'-Adult-SmallIntestine\|Adult / Celltypes from developing, pediatric, Crohn's, & adult GI tract	CYP3A4 CYP3A5 NR1H4 UGT2A3	5.24e-05	199	46	4	a5fffe381be1ba7d192b68d1d3937ce47663658e
ToppCell	5'-Adult-SmallIntestine-Epithelial-mature_enterocytic\|Adult / Celltypes from developing, pediatric, Crohn's, & adult GI tract	CYP3A4 CYP3A5 NR1H4 UGT2A3	5.24e-05	199	46	4	01c2721bc82cd672e9477029b4a7ecc77e2f1b00
ToppCell	3'-Child04-06-SmallIntestine-Epithelial\|Child04-06 / Celltypes from developing, pediatric, Crohn's, & adult GI tract	CLDN7 CYP3A4 CYP3A5 UGT2A3	5.24e-05	199	46	4	ab71b312635a2b2c98d71b60a299f44bc80a3587
ToppCell	Biopsy_IPF-Epithelial-MUC5B+\|Biopsy_IPF / Sample group, Lineage and Cell type	RDH10 B3GALT5 CLDN7 FGFR2	5.34e-05	200	46	4	f0a6747f6d37ec6d261bd649ac678c39cca5e4c8
Drug	THDCA	CYP3A4 CYP3A5 NR1H4	2.18e-06	13	46	3	CID000119046
Drug	4-hydroxymidazolam	CYP3A4 CYP3A5	3.99e-06	2	46	2	ctd:C042940
Drug	norverapamil	CYP3A4 CYP3A5	3.99e-06	2	46	2	ctd:C016904
Drug	5,6-dihydro-2H-pyran-2-one	CYP3A4 CYP3A5	3.99e-06	2	46	2	CID000520660
Drug	6 beta-hydroxytestosterone	CYP3A4 CYP3A5	3.99e-06	2	46	2	ctd:C025591
Drug	notopterol	CYP3A4 CYP3A5	3.99e-06	2	46	2	CID005320227
Drug	N-acetyl-S--(1,2,3,4,4-pentachlorobutadienyl)cysteine sulfoxide	CYP3A4 CYP3A5	3.99e-06	2	46	2	ctd:C114289
Drug	CQA 206-291	CYP3A4 CYP3A5	3.99e-06	2	46	2	ctd:C059483
Drug	fructus schizandrae, radix ginseng, radix ophiopogonis drug combination	CYP3A4 CYP3A5	3.99e-06	2	46	2	ctd:C009252
Drug	erythralosamine	CYP3A4 CYP3A5	1.20e-05	3	46	2	CID000352196
Drug	3-methoxymorphinan	CYP3A4 CYP3A5	1.20e-05	3	46	2	ctd:C028657
Drug	dechloroethylcyclophosphamide	CYP3A4 CYP3A5	1.20e-05	3	46	2	ctd:C064445
Drug	6 beta-hydroxydexamethasone	CYP3A4 CYP3A5	1.20e-05	3	46	2	CID000063050
Drug	territrem C	CYP3A4 CYP3A5	1.20e-05	3	46	2	CID000160306
Drug	N-acetyl-S-pentachloro-1,3-butadienylcysteine	CYP3A4 CYP3A5	1.20e-05	3	46	2	ctd:C049739
Drug	1-hydroxymethylmidazolam	CYP3A4 CYP3A5	1.20e-05	3	46	2	ctd:C040081
Drug	synthetic pyrethrins	CACNA1A CYP3A4 CYP3A5 ADCY6	1.28e-05	71	46	4	CID000002982
Drug	senecionine	CYP3A4 CYP3A5 NR1H4 UGT2A3	1.51e-05	74	46	4	ctd:C009237
Drug	N-nitrosodipropylamine	CACNA1A CYP3A4 CYP3A5	1.94e-05	26	46	3	CID000012130
Drug	androstenol	CYP3A4 CYP3A5 NR1H4	2.18e-05	27	46	3	CID000101989
Drug	tirucallol	ABCG4 FGFR2 CYP3A5 NR1H4	2.27e-05	82	46	4	CID000000856
Drug	B253	CYP3A4 CYP3A5	2.39e-05	4	46	2	CID000021540
Drug	rifamycin analog	CYP3A4 NR1H4	2.39e-05	4	46	2	CID009574292
Drug	5-methoxyflavone	CYP3A4 CYP3A5	2.39e-05	4	46	2	CID000094525
Drug	azacyclonol	CYP3A4 CYP3A5	2.39e-05	4	46	2	CID000015722
Drug	Ro 23-7637	CYP3A4 CYP3A5	2.39e-05	4	46	2	CID000129491
Drug	N-ethyl-3-toluamide	CYP3A4 CYP3A5	2.39e-05	4	46	2	ctd:C454678
Drug	hydroxytrimipramine	CYP3A4 CYP3A5	2.39e-05	4	46	2	CID000160610
Drug	CQA 206-291	CYP3A4 CYP3A5	2.39e-05	4	46	2	CID000146782
Drug	eucalyptol	CYP3A4 CYP3A5	2.39e-05	4	46	2	ctd:C010087
Drug	territrem B	CYP3A4 CYP3A5	2.39e-05	4	46	2	CID000114734
Drug	3 C3	CYP3A4 CYP3A5 NR1H4	3.02e-05	30	46	3	CID006857689
Drug	1-methylxanthine (1-MX	CYP3A4 CYP3A5 NAA16	3.33e-05	31	46	3	CID000080220
Drug	methoxy-morpholinyl-doxorubicin	CYP3A4 NR1H4	3.98e-05	5	46	2	ctd:C066998
Drug	NSC-687962	CYP3A4 CYP3A5	3.98e-05	5	46	2	CID000390521
Drug	6 beta-hydroxyprednisolone	CYP3A4 CYP3A5	3.98e-05	5	46	2	CID000152139
Drug	M 0772	CYP3A4 CYP3A5	3.98e-05	5	46	2	CID000032485
Drug	2Cmp	CYP3A4 CYP3A5	3.98e-05	5	46	2	CID000023392
Drug	ethyl isocyanate	CYP3A4 CYP3A5	3.98e-05	5	46	2	CID000008022
Drug	methyl-2-hydroxypropylnitrosamine	CACNA1A CYP3A5	3.98e-05	5	46	2	CID000107719
Drug	1,4-cineole	CYP3A4 CYP3A5	3.98e-05	5	46	2	CID000010106
Drug	Fluvoxamine maleate [61718-82-9]; Up 200; 9.2uM; HL60; HT_HG-U133A	ABCG4 CLDN7 FGFR2 PFKL NUP160	4.62e-05	196	46	5	2913_UP
Drug	Apramycin [37321-09-8]; Up 200; 7.4uM; PC3; HT_HG-U133A	ABCG4 FGFR2 CYP3A5 DNAH9 ADCY6	4.74e-05	197	46	5	6614_UP
Drug	3-[(3S,5R,10S,13R,14S,17R)-3-[(2S,4R,5R,6S)-4,5-dihydroxy-6-methyloxan-2-yl]oxy-14-hydroxy-10,13-dimethyl-1,2,3,4,5,6,7,8,9,11,12,15,16,17-tetradecahydrocyclopenta[a]phenanthren-17-yl]-2H-furan-5-one	CYP3A4 CYP3A5 UGT2A3	4.83e-05	35	46	3	CID010436171
Drug	II-E	IVD CYP3A4 CYP3A5 POLR2B	5.16e-05	101	46	4	CID006540268
Drug	skatole	CHD8 CYP3A4 CYP3A5	5.71e-05	37	46	3	CID000006736
Drug	hydrocotarnine	CYP3A4 CYP3A5	5.96e-05	6	46	2	CID000003646
Drug	4'-methoxyflavone	CYP3A4 CYP3A5	5.96e-05	6	46	2	CID000077793
Drug	N-desmethyltamoxifen	CYP3A4 CYP3A5	5.96e-05	6	46	2	ctd:C028787
Drug	PCB54	CYP3A4 CYP3A5	5.96e-05	6	46	2	CID000027588
Drug	droloxifene	CYP3A4 CYP3A5	5.96e-05	6	46	2	ctd:C038345
Drug	AC1NB6CQ	CYP3A4 CYP3A5	5.96e-05	6	46	2	CID004488117
Drug	3-hydroxyacetaminophen	CYP3A4 CYP3A5	5.96e-05	6	46	2	CID000161950
Drug	xanthotoxol	CYP3A4 CYP3A5	5.96e-05	6	46	2	CID000065090
Drug	climbazole	CYP3A4 CYP3A5	5.96e-05	6	46	2	CID000037907
Drug	carbosulfan	CYP3A4 CYP3A5	5.96e-05	6	46	2	ctd:C035038
Drug	2,3,6-trichlorophenol	CYP3A4 CYP3A5	5.96e-05	6	46	2	CID000013618
Drug	N-nitrosomethyl(2-oxopropyl)amine	CACNA1A CYP3A5	5.96e-05	6	46	2	CID000104910
Drug	4-bromoestradiol	CYP3A4 CYP3A5	5.96e-05	6	46	2	CID000266502
Drug	Alfentanil	CYP3A4 CYP3A5	5.96e-05	6	46	2	ctd:D015760
Drug	butachlor	CYP3A4 NR1H4	5.96e-05	6	46	2	ctd:C054409
Drug	AC1L330W	CYP3A4 CYP3A5	5.96e-05	6	46	2	CID000107939
Drug	DMNM	CACNA1A CYP3A5	5.96e-05	6	46	2	CID000015081
Drug	lanosol	CYP3A4 CYP3A5	5.96e-05	6	46	2	CID000078659
Drug	1H-3	CYP3A4 CYP3A5 NR1H4	6.20e-05	38	46	3	CID000043849
Drug	endrine	NCBP1 CYP3A4 CYP3A5 ADCY6	6.23e-05	106	46	4	CID000003048
Drug	arabinosyluracil	B3GALT5 PFKL CYP3A4 CYP3A5 UGT2A3 EIF4G2	7.51e-05	354	46	6	CID000001177
Drug	AC1Q6O8B	CYP3A4 CYP3A5 NR1H4	7.80e-05	41	46	3	CID000000334
Drug	4-formylbiphenyl	CYP3A4 CYP3A5	8.33e-05	7	46	2	CID000076689
Drug	4-phenylbutyl isothiocyanate	CYP3A4 CYP3A5	8.33e-05	7	46	2	CID000124881
Drug	2,4,7-trinitro-9H-fluorene	CYP3A4 CYP3A5	8.33e-05	7	46	2	CID000214794
Drug	pentachlorothiophenol	CYP3A4 CYP3A5	8.33e-05	7	46	2	CID000008620
Drug	S-13	CYP3A4 CYP3A5	8.33e-05	7	46	2	CID000189036
Drug	AC1L1BIH	PTGER2 CYP3A5	8.33e-05	7	46	2	CID000001453
Drug	em-4	CYP3A4 CYP3A5	8.33e-05	7	46	2	CID000433037
Drug	5-hydroxydiclofenac	CYP3A4 CYP3A5	8.33e-05	7	46	2	ctd:C117715
Drug	desmethyltrimipramine	CYP3A4 CYP3A5	8.33e-05	7	46	2	CID000160632
Drug	Hpp(+)	CYP3A4 CYP3A5	8.33e-05	7	46	2	CID000130810
Drug	4-vinylcyclohexene	CYP3A4 CYP3A5	8.33e-05	7	46	2	CID000007499
Drug	norfluoxetine	CYP3A4 CYP3A5	8.33e-05	7	46	2	ctd:C036139
Drug	Dextrorphan	CYP3A4 CYP3A5	8.33e-05	7	46	2	ctd:D003917
Drug	butylphenol	CYP3A4 CYP3A5	8.33e-05	7	46	2	CID000018515
Drug	3-hydroxycoumarin	CYP3A4 CYP3A5	8.33e-05	7	46	2	CID000013650
Drug	1,3,7-trimethyluric acid	CYP3A4 CYP3A5	8.33e-05	7	46	2	CID000079437
Drug	4-(4-chlorobenzyl)pyridine	CYP3A4 CYP3A5	8.33e-05	7	46	2	CID000078124
Drug	AC1L4F1M	CYP3A4 CYP3A5	8.33e-05	7	46	2	CID000205626
Drug	HMS2232N07	CYP3A4 NR1H4	8.33e-05	7	46	2	CID000072111
Drug	Cf3-cl4-biphenyl	CYP3A4 CYP3A5	8.33e-05	7	46	2	CID000128938
Drug	16-O-demethylaconitine	CYP3A4 CYP3A5	8.33e-05	7	46	2	ctd:C486136
Drug	2beta-hydroxytestosterone	CYP3A4 CYP3A5	8.33e-05	7	46	2	CID005207588
Drug	Voriconazole	CYP3A4 CYP3A5	8.33e-05	7	46	2	ctd:D065819
Drug	2-cyclohexyl-2-hydroxy-2-phenylacetate	CYP3A4 CYP3A5	8.33e-05	7	46	2	CID000097700
Drug	N-nitrosobis(2-acetoxypropyl)amine	CACNA1A CYP3A5	8.33e-05	7	46	2	CID000091675
Drug	lithocholic acid	CYP3A4 CYP3A5 NR1H4 MEN1	8.85e-05	116	46	4	CID000009903
Drug	exemestane	ABCG4 CYP3A4 CYP3A5	9.00e-05	43	46	3	CID000060198
Drug	alpha-naphthoflavone	CACNA1A CYP3A4 CYP3A5 UGT2A3	9.46e-05	118	46	4	CID000011790
Drug	zoxazolamine	CYP3A4 CYP3A5 NR1H4	9.65e-05	44	46	3	CID000006103
Drug	ipriflavone	CHD8 CYP3A4 CYP3A5	1.03e-04	45	46	3	CID000003747
Drug	4 A 3	CYP3A4 CYP3A5 NR1H4	1.10e-04	46	46	3	CID000137566
Drug	territrem A	CYP3A4 CYP3A5	1.11e-04	8	46	2	CID000115079
Disease	tacrolimus measurement	CYP3A4 CYP3A5	1.30e-05	4	44	2	EFO_0008458
Disease	testosterone measurement	IVD EFL1 CYP3A4 TRAPPC12 NUP160 ADCY6 NR1H4 AGMO DUSP16	9.22e-05	1275	44	9	EFO_0004908
Disease	metabolonic lactone sulfate measurement	CYP3A4 CYP3A5	3.66e-04	19	44	2	EFO_0800659
Disease	phosphatidylcholine 34:2 measurement	CACNA1A B3GALT5	4.06e-04	20	44	2	EFO_0010376
Disease	forced expiratory volume	IVD CLDN7 FGFR2 CYP3A4 CEP95 AGMO	1.06e-03	789	44	6	EFO_0004314

Protein segments in the cluster

Peptide	Gene	Start	Entry
NLRYFEMCILMVIAM	CACNA1A	1241	O00555
KMSCYIMQDDMLLPH	ABCG4	141	Q9H172
MPNLLNTMMELRKCC	CHD8	1081	Q9HCK8
IMETLRCLMFLMLYR	AGMO	391	Q6ZNB7
ITALADYAMRLMEQM	ADCY6	1056	O43306
CIGMRFALMNMKLAL	CYP3A5	441	P20815
KPQRLMAAMYTCDIM	EFL1	976	Q7Z2Z2
MYFLMSSNIRKIMCQ	GPR34	326	Q9UPC5
MAFPKMRLMYICLLV	B3GALT5	1	Q9Y2C3
TICYVMMMPFKRQAL	HNRNPLL	101	Q8WVV9
MTCEKVLDLMCYMVL	INTS10	511	Q9NVR2
MDMYMRRKCQECRLR	NR1H4	181	Q96RI1
MCIYFQLLLMETTAM	PABIR3	146	Q6P4D5
SYMRCDRKMEVAFMV	MEN1	231	O00255
VEMLQCESYKRRMMA	ANKAR	706	Q7Z5J8
CESYKRRMMAVMSLE	ANKAR	711	Q7Z5J8
ESGSLDIMKMLLMYC	FEM1C	191	Q96JP0
RMDKPANCTNELYMM	FGFR2	721	P21802
GCLMQMYFMIALAKA	OR1A2	96	Q9Y585
LAQATEMLYMRLDTM	NCBP1	391	Q09161
VAILLYKVACNMMMK	EDRF1	456	Q3B7T1
NCIGMRFALMNMKLA	CYP3A4	441	P08684
LMLKMLAQYRISMAA	PFKL	746	P17858
LATMLMLFAMALERY	PTGER2	121	P43116
YMLRANMIKEAEEMC	NAA16	451	Q6N069
QGKMADMYTRLMACR	IVD	326	P26440
MMQCLIRKLAALSQY	RASGEF1B	156	Q0VAM2
KSLMDQYFARMCSLM	EIF4G2	271	P78344
IAYIMKRMDMSLDEA	DUSP16	256	Q9BY84
DDYRVQLCAKMMRMR	CEP95	671	Q96GE4
LCMLRAMRPDRMTYA	DNAH9	3851	Q9NYC9
VMYFIMLFCITMKRQ	RER1	151	O15258
SQMVMKMREYLCNLH	DARS2	191	Q6PI48
MLKYMKMTATCLLLP	SAMD3	396	Q8N6K7
ACMDDMLLSVMAYDR	OR7E24	126	Q6IFN5
MLAYSLKLCMSLMQN	PSMD1	176	Q99460
MPYACKLLFQELMSM	POLR2B	1151	P30876
DKFYMLMRMVLNESL	RRP1	116	P56182
CCKERFEVKMMLMNL	SDAD1	306	Q9NVU7
HKLRMWSYKEQMCLM	NUP160	306	Q12769
MICTPRLMYIVTFMK	RDH10	286	Q8IZV5
SMNLNVRSMYLMIKA	BDH2	101	Q9BUT1
MMSCKMYDSVLALSA	CLDN7	61	O95471
RVMYSMANCLLLMKD	TRAPPC12	546	Q8WVT3
IMKQSYICALIAMMA	PIEZO2	496	Q9H5I5
ACEMYTRAANMFKMA	NAPB	41	Q9H115
LKMMCESFIYNQTLM	UGT2A3	121	Q6UWM9